EYEPOINT PHARMACEUTICALS, INC Price to Book Ratio 2006-2021 | EYPT

Historical price to book ratio values for EYEPOINT PHARMACEUTICALS, INC (EYPT) over the last 10 years. The current price to book ratio for EYEPOINT PHARMACEUTICALS, INC as of October 15, 2021 is 3.08.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

EYEPOINT PHARMACEUTICALS, INC Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-15 11.44 3.08
2021-06-30 8.99 $3.72 2.42
2021-03-31 10.16 $4.03 2.52
2020-12-31 6.58 $1.02 6.44
2020-09-30 5.18 $0.58 8.97
2020-06-30 7.57 $0.33 22.63
2020-03-31 10.20 $1.32 7.72
2019-12-31 15.50 $0.76 20.36
2019-09-30 18.10 $1.48 12.27
2019-06-30 16.40 $2.65 6.18
2019-03-31 17.90 $2.08 8.60
2018-12-31 18.90 0.00
2018-09-30 35.70 $5.04 7.09
2018-06-30 20.80 $1.57 13.26
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.329B $0.034B
EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known as pSivida Corp., is headquartered in Watertown, MA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00